PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-9

  1. 598 Posts.
    lightbulb Created with Sketch. 138

    I think PAR is ok with the delay as it will allow them to get 12 month 008 data and then discuss with regulators to hopefully incorporate DMOAD into stage 2 and confirmatory.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.